



Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

Sabrina C. Cecere¹, Sabrina Rossetti¹, Carla Cavaliere², Chiara Della Pepa¹, Marilena Di Napoli¹, Anna Crispo³, Gelsomina Iovane¹, Raffaele Piscitelli⁴, Domenico Sorrentino⁵, Gennaro Ciliberto⁶, Piera Maiolino⁴, Paolo Muto⁷, Sisto Perdonà⁵, Massimiliano Berretta⁸, Sandro Pignata¹, Gaetano Facchini^{1*} and Carmine D’Aniello⁹

¹ Division of Medical Oncology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy, ² Department of Onco-Ematology Medical Oncology, S.G. Moscati Hospital of Taranto, Taranto, Italy, ³ Unit of Epidemiology, Struttura Complessa di Statistica Medica, Biometria e Bioinformatica, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy, ⁴ Pharmacy Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy, ⁵ Division of Urology, Department of Uro-Gynaecological Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy, ⁶ Scientific Direction, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy, ⁷ Division of Radiation Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale,” Naples, Italy, ⁸ Division of Medical Oncology–Centro di Riferimento Oncologico, Aviano, Italy, ⁹ Oncology Unit, A.O.R.N. dei COLLI “Ospedali Monaldi-Cotugno-CTO,” Naples, Italy

OPEN ACCESS

Edited and reviewed by:

Giovanni Li Volti,
University of Catania, Italy

*Correspondence:

Gaetano Facchini
gafacchi@libero.it

Specialty section:

This article was submitted to
Experimental Pharmacology and Drug
Discovery,
a section of the journal
Frontiers in Pharmacology

Received: 10 October 2016

Accepted: 18 November 2016

Published: 05 December 2016

Citation:

Cecere SC, Rossetti S, Cavaliere C, Della Pepa C, Di Napoli M, Crispo A, Iovane G, Piscitelli R, Sorrentino D, Ciliberto G, Maiolino P, Muto P, Perdonà S, Berretta M, Pignata S, Facchini G and D’Aniello C (2016) Corrigendum: Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale.” *Front. Pharmacol.* 7:468. doi: 10.3389/fphar.2016.00468

Keywords: pazopanib, metastatic renal cancer, real world, angiogenesis inhibitors, treatment

A corrigendum on

Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”

by Cecere, S. C., Rossetti, S., Cavaliere, C., Della Pepa, C., Di Napoli, M., Crispo, A., et al. (2016). *Front. Pharmacol.* 7:287. doi: 10.3389/fphar.2016.00287

In the original article, we have neglected to thank our funder, Novartis Farma S.p.A. The Funding Statement appears below.

FUNDING

Novartis Farma S.p.A. supported publication of this article.

The authors apologize for this oversight. This error does not change the scientific conclusions of the article in any way.

Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Cecere, Rossetti, Cavaliere, Della Pepa, Di Napoli, Crispo, Iovane, Piscitelli, Sorrentino, Ciliberto, Maiolino, Muto, Perdonà, Berretta, Pignata, Facchini and D’Aniello. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.